Estrella Immunopharma (ESLA) Competitors $1.05 +0.09 (+9.38%) Closing price 03:59 PM EasternExtended Trading$1.03 -0.02 (-1.43%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. CTOR, FATE, HURA, CGEN, ACOG, GNLX, IKT, SCLX, CHRS, and CGTXShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Citius Oncology (CTOR), Fate Therapeutics (FATE), TuHURA Biosciences (HURA), Compugen (CGEN), Alpha Cognition (ACOG), Genelux (GNLX), Inhibikase Therapeutics (IKT), Scilex (SCLX), Coherus Oncology (CHRS), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Its Competitors Citius Oncology Fate Therapeutics TuHURA Biosciences Compugen Alpha Cognition Genelux Inhibikase Therapeutics Scilex Coherus Oncology Cognition Therapeutics Estrella Immunopharma (NASDAQ:ESLA) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Do analysts prefer ESLA or CTOR? Estrella Immunopharma currently has a consensus price target of $16.00, indicating a potential upside of 1,423.81%. Citius Oncology has a consensus price target of $3.00, indicating a potential upside of 38.25%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals believe in ESLA or CTOR? 0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by insiders. Comparatively, 4.6% of Citius Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer ESLA or CTOR? In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 1.87 beat Citius Oncology's score of 0.94 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Overall Sentiment Estrella Immunopharma Very Positive Citius Oncology Positive Which has more risk & volatility, ESLA or CTOR? Estrella Immunopharma has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500. Which has higher valuation & earnings, ESLA or CTOR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/AN/A-$0.26-4.04Citius OncologyN/AN/AN/AN/AN/A Is ESLA or CTOR more profitable? Citius Oncology's return on equity of -51.93% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -1,132.38% -358.54% Citius Oncology N/A -51.93%-22.17% SummaryEstrella Immunopharma beats Citius Oncology on 5 of the 9 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.92M$3.08B$5.76B$9.75BDividend YieldN/A2.26%3.96%4.02%P/E Ratio-4.0420.9242.8226.39Price / SalesN/A355.43431.37159.28Price / CashN/A44.7137.7559.42Price / Book-6.568.0410.566.59Net IncomeN/A-$53.98M$3.27B$265.83M7 Day Performance8.26%-0.88%0.61%0.18%1 Month Performance16.28%5.67%5.43%2.13%1 Year Performance-9.09%9.07%50.37%21.07% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma3.1086 of 5 stars$1.05+9.4%$16.00+1,423.8%-18.6%$38.92MN/A-4.04N/APositive NewsGap UpCTORCitius Oncology1.2439 of 5 stars$1.70-2.9%$3.00+76.5%+30.9%$133.23MN/A0.00N/AGap UpFATEFate Therapeutics3.8491 of 5 stars$1.14-5.0%$3.58+214.3%-69.2%$131.48M$8.47M-0.79550HURATuHURA Biosciences1.8156 of 5 stars$3.00-2.9%$12.67+322.2%N/A$131.04MN/A0.00N/ACGENCompugen1.8823 of 5 stars$1.46-5.8%$4.00+174.0%-26.3%$130.29M$27.86M-6.6470News CoveragePositive NewsACOGAlpha Cognition2.4134 of 5 stars$8.09-4.1%$20.00+147.2%N/A$129.60MN/A-5.06N/APositive NewsGNLXGenelux1.8569 of 5 stars$3.43-3.1%$17.75+417.5%+78.3%$129.55M$10K-3.9910News CoveragePositive NewsIKTInhibikase Therapeutics2.0408 of 5 stars$1.70-1.2%$6.50+282.4%+32.4%$126.38MN/A-0.646SCLXScilex2.218 of 5 stars$17.96-7.3%$455.00+2,433.4%-53.1%$125.00M$56.59M-0.6280High Trading VolumeCHRSCoherus Oncology4.349 of 5 stars$1.07flat$4.68+337.7%-13.2%$124.37M$266.96M0.69330Positive NewsCGTXCognition Therapeutics2.4052 of 5 stars$1.67+12.1%$2.83+69.7%+262.0%$122.70MN/A-2.4920Gap Up Related Companies and Tools Related Companies Citius Oncology Competitors Fate Therapeutics Competitors TuHURA Biosciences Competitors Compugen Competitors Alpha Cognition Competitors Genelux Competitors Inhibikase Therapeutics Competitors Scilex Competitors Coherus Oncology Competitors Cognition Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access